$TCRT
Alaunos Therapeutics, Inc.

2018 Q1 Form 10-K Financial Statement

#000119312518067077 Filed on March 01, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2016 Q4 2016 Q3
Revenue $146.0K $1.600M $1.600M
YoY Change -90.86% -16.67% -14.44%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.160M $3.320M $3.540M
YoY Change 71.11% 1.84% 15.31%
% of Gross Profit
Research & Development $10.18M $9.390M $8.975M
YoY Change -14.91% 15.36% -47.11%
% of Gross Profit
Depreciation & Amortization $117.0K $60.00K $70.00K
YoY Change 46.25% 0.0% 16.67%
% of Gross Profit
Operating Expenses $16.34M $12.71M $8.975M
YoY Change 36.56% 11.49% -47.11%
Operating Profit -$16.20M -$11.11M -$10.91M
YoY Change 15.98% 17.18% -39.92%
Interest Expense $30.00K -$150.0K $20.00K
YoY Change -101.92%
% of Operating Profit
Other Income/Expense, Net $148.0K $30.00K $39.00K
YoY Change 289.47% 200.0% -1075.0%
Pretax Income -$16.02M -$11.22M -$10.85M
YoY Change 3.42% 18.35% -40.29%
Income Tax
% Of Pretax Income
Net Earnings -$21.14M -$14.76M -$14.45M
YoY Change 7.54% 55.72% -20.5%
Net Earnings / Revenue -14479.45% -922.25% -902.81%
Basic Earnings Per Share -$0.15
Diluted Earnings Per Share -$0.15 -$0.11 -$0.11
COMMON SHARES
Basic Shares Outstanding 142.4M shares 131.7M shares 131.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2016 Q4 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $51.10M $81.10M $94.70M
YoY Change -23.04% -42.36% -42.19%
Cash & Equivalents $51.11M $81.05M $94.68M
Short-Term Investments
Other Short-Term Assets $21.00M $23.80M $21.00M
YoY Change -19.85% 108.77% 153.01%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00 $0.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $72.12M $104.9M $115.7M
YoY Change -22.25% -31.23% -32.93%
LONG-TERM ASSETS
Property, Plant & Equipment $1.244M $843.0K $825.0K
YoY Change 10.68% 45.09% 214.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $13.97M $493.0K $492.0K
YoY Change 2740.24% -0.2% 0.2%
Total Long-Term Assets $15.35M $1.464M $1.445M
YoY Change 779.93% 21.7% 64.02%
TOTAL ASSETS
Total Short-Term Assets $72.12M $104.9M $115.7M
Total Long-Term Assets $15.35M $1.464M $1.445M
Total Assets $87.46M $106.3M $117.1M
YoY Change -7.44% -30.82% -32.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $606.0K $156.0K $1.814M
YoY Change 168.14% -92.23% -56.33%
Accrued Expenses $8.878M $9.109M $7.364M
YoY Change -16.93% 2.28% -59.4%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.06M $15.81M $15.74M
YoY Change -42.38% -12.77% -46.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $51.50M $42.50M $44.00M
YoY Change 21.18% -11.83% -11.82%
Total Long-Term Liabilities $51.50M $42.50M $44.00M
YoY Change 21.18% -11.83% -11.82%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.06M $15.81M $15.74M
Total Long-Term Liabilities $51.50M $42.50M $44.00M
Total Liabilities $61.57M $58.33M $59.73M
YoY Change 2.7% -12.1% -24.89%
SHAREHOLDERS EQUITY
Retained Earnings -$736.6M -$658.0M -$646.8M
YoY Change 9.35% 33.55% 33.85%
Common Stock $613.4M $580.7M $582.4M
YoY Change 6.0% 0.11% 0.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$123.1M -$77.30M -$64.42M
YoY Change
Total Liabilities & Shareholders Equity $87.46M $106.3M $117.1M
YoY Change -7.44% -30.82% -32.44%

Cashflow Statement

Concept 2018 Q1 2016 Q4 2016 Q3
OPERATING ACTIVITIES
Net Income -$21.14M -$14.76M -$14.45M
YoY Change 7.54% 55.72% -20.5%
Depreciation, Depletion And Amortization $117.0K $60.00K $70.00K
YoY Change 46.25% 0.0% 16.67%
Cash From Operating Activities -$18.96M -$13.07M -$14.11M
YoY Change 32.75% -45.08% -131.22%
INVESTING ACTIVITIES
Capital Expenditures $150.0K $80.00K $210.0K
YoY Change -58.1% -78.95% 2000.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$150.0K -$80.00K -$210.0K
YoY Change -58.33% -78.95% 2000.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $731.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -731.0K -490.0K 0.000
YoY Change -2536.67% -145.79% -100.0%
NET CHANGE
Cash From Operating Activities -18.96M -13.07M -14.11M
Cash From Investing Activities -150.0K -80.00K -210.0K
Cash From Financing Activities -731.0K -490.0K 0.000
Net Change In Cash -19.84M -13.64M -14.32M
YoY Change 35.78% -40.98% -131.63%
FREE CASH FLOW
Cash From Operating Activities -$18.96M -$13.07M -$14.11M
Capital Expenditures $150.0K $80.00K $210.0K
Free Cash Flow -$19.11M -$13.15M -$14.32M
YoY Change 30.53% -45.62% -131.69%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
4.893
CY2017Q2 ziop Public Offering Net Price Per Share
PublicOfferingNetPricePerShare
5.15
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
142398936 shares
CY2006Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2006Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2006Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2006Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2006Q2 ziop Shares Authorized
SharesAuthorized
280000000 shares
CY2016Q2 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
694000
CY2017Q2 dei Entity Public Float
EntityPublicFloat
808804937
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6505663 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.07
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
33841000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
238000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42803000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3481468 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.96
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
87371000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
140717000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
132376670 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
132376670 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2671835 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.40
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3465335 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.07
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-657997000
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Liabilities
Liabilities
58325000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
106348000
CY2016Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
862000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6389000
CY2016Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
281000
CY2016Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
56000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
156000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-77298000
CY2016Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
862000
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
41528000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
132000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
580567000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3262000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
488000
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
126000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
646000
CY2016Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1446000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
28000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15809000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
226798000
CY2016Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
155000
CY2016Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
294000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9109000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
104884000
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1537000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
2014000
CY2016Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
18636000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
843000
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3383000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
81053000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
100790000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
34845000
CY2016Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4105000
CY2016Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
21000
CY2016Q4 us-gaap Assets
Assets
106348000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
226798000
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
493000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
23810000
CY2016Q4 ziop Deferred Tax Assets Capitalized Acquisition Costs
DeferredTaxAssetsCapitalizedAcquisitionCosts
9389000
CY2016Q4 ziop Deferred Tax Assets Depreciation
DeferredTaxAssetsDepreciation
227000
CY2016Q4 ziop Accrued Consulting Fees Current
AccruedConsultingFeesCurrent
2342000
CY2016Q4 ziop Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
1116000
CY2016Q4 ziop Deferred Tax Assets Start Up And Organizational Costs
DeferredTaxAssetsStartUpAndOrganizationalCosts
59360000
CY2016Q4 ziop Accrued Preclinical Services Current
AccruedPreclinicalServicesCurrent
2693000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
142658037 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
303928 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
142658037 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2925502 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.12
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3852135 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.12
CY2017Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
526364 shares
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-712442000
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
3077000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
723000
CY2017Q4 us-gaap Liabilities
Liabilities
58420000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
105606000
CY2017Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2424000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6389000
CY2017Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
145000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4417000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-96806000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
489000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1129000
CY2017Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
2424000
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
35139000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
143000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
615493000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3631000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
256000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
736000
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
1017000
CY2017Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1919000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
222000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20856000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
178388000
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
141000
CY2017Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
361000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9909000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
90783000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
993000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
1330000
CY2017Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
11126000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals
OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals
278000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1211000
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1152000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70946000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
89098000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
32395000
CY2017Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4842000
CY2017Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
19000
CY2017Q4 us-gaap Assets
Assets
105606000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
178388000
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
13484000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
19818000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1152000
CY2017Q4 ziop Deferred Tax Assets Capitalized Acquisition Costs
DeferredTaxAssetsCapitalizedAcquisitionCosts
5822000
CY2017Q4 ziop Operating Leases Future Minimum Payments Due Net
OperatingLeasesFutureMinimumPaymentsDueNet
2799000
CY2017Q4 ziop Deferred Tax Assets Depreciation
DeferredTaxAssetsDepreciation
136000
CY2017Q4 ziop Accrued Consulting Fees Current
AccruedConsultingFeesCurrent
3022000
CY2017Q4 ziop Operating Leases Future Minimum Payments Due In Five Years And Thereafter
OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter
0
CY2017Q4 ziop Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
902000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8681 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.05 pure
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.36
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.47
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7913 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0146 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
202835 shares
CY2017Q4 ziop Deferred Tax Assets Start Up And Organizational Costs
DeferredTaxAssetsStartUpAndOrganizationalCosts
37488000
CY2017Q4 ziop Accrued Preclinical Services Current
AccruedPreclinicalServicesCurrent
2210000
CY2017Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
9708738 shares
CY2017Q2 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
47300000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-124000
ziop Embedded Derivative Dividend Amount
EmbeddedDerivativeDividendAmount
44000
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5067856 shares
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.41 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.01 pure
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-10000
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.95
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.47
CY2015 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
-218000
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
125416084 shares
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.03 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.00 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0193 pure
CY2015 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3249160 shares
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.96
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
427800 shares
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
412000
CY2015 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
34000
CY2015 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
3000
CY2015 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2015 us-gaap Contracts Revenue
ContractsRevenue
4332000
CY2015 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
67285000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-120100000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-120088000
CY2015 us-gaap Interest Paid
InterestPaid
0
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7997000
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
0
CY2015 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4568000
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
94320000
CY2015 us-gaap Stock Issued1
StockIssued1
67285000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
12000
CY2015 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-120088000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
10214000
CY2015 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
301000
CY2015 us-gaap Depreciation
Depreciation
357000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4000
CY2015 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-189000
CY2015 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
67285000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-412000
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
94320000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
7997000
CY2015 us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
34000
CY2015 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
0
CY2015 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0
CY2015 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
7997000
CY2015 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
47000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
53418000
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17647000
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1724000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
98336000
CY2015 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
124432000
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1000000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
106785000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
23800000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
97914000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4568000
CY2015 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
518000
CY2015 ziop Common Stock Issuance Cost
CommonStockIssuanceCost
6305000
CY2015 ziop Unrecognized Tax Benefits Reduction Resulting From Prior Period Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionResultingFromPriorPeriodLapseOfApplicableStatuteOfLimitations
20000
CY2015 ziop Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
0
CY2015 ziop Effective Income Tax Rate Reconciliation Collaboration Agreement
EffectiveIncomeTaxRateReconciliationCollaborationAgreement
0.00 pure
CY2015 ziop Payment For Issuance Of Restricted Common Stock
PaymentForIssuanceOfRestrictedCommonStock
518000
CY2015 ziop Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development True Up
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp
0.00 pure
CY2015 ziop Effective Income Tax Rate Reconciliation Nondeductible Expense Officers Compensation
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation
0.00 pure
CY2015 ziop Effective Income Tax Rate Reconciliation Nondeductible Expense Federal Rate Change
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange
0.00 pure
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
40295218 shares
CY2017 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2017 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017 dei Document Type
DocumentType
10-K
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.96 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.01 pure
CY2017 dei Entity Central Index Key
EntityCentralIndexKey
0001107421
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-54669000
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y5M20D
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.67
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8103 pure
CY2017 dei Trading Symbol
TradingSymbol
ZIOP
CY2017 dei Amendment Flag
AmendmentFlag
false
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Concentrations of Credit Risk</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents.</p> </div>
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.04 pure
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.64
CY2017 us-gaap Research And Development Arrangement Contract To Perform For Others Description And Terms
ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms
Pursuant to the Research and Development Agreement, the Company, Intrexon and MD Anderson have agreed to form a joint steering committee that will oversee and manage the new and ongoing research programs. As provided under the MD Anderson License, the Company will provide funding for research and development activities in support of the research programs under the Research and Development Agreement for a period of three years and in an amount of no less than $15.0 million and no greater than $20.0 million per year.
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.27
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8031 pure
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0185 pure
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y6M29D
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
122000 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.94
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
136938264 shares
CY2017 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.03 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.03 pure
CY2017 dei Document Period End Date
DocumentPeriodEndDate
2017-12-31
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0227 pure
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
180000 shares
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The Company&#x2019;s most significant estimates and judgments used in the preparation of our financial statements are:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Clinical trial expenses;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Collaboration agreements;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Fair value measurements of stock-based compensation and Series 1 preferred stock (and related dividends); and</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Income taxes.</td> </tr> </table> </div>
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.53
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00 pure
CY2017 dei Entity Registrant Name
EntityRegistrantName
ZIOPHARM ONCOLOGY INC
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-139000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-737000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
688800 shares
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-48400000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
737000
CY2017 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
12991000
CY2017 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2017 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1295000
CY2017 us-gaap Contracts Revenue
ContractsRevenue
6389000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-53493000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-54323000
CY2017 us-gaap Interest Paid
InterestPaid
0
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8454000
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
0
CY2017 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
88000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
47270000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
465000
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-73261000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3992000
CY2017 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-2000
CY2017 us-gaap Depreciation
Depreciation
369000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4261000
CY2017 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
18938000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
47270000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
8454000
CY2017 us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
2059000
CY2017 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
0
CY2017 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0
CY2017 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
8454000
CY2017 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
90000
CY2017 us-gaap Dividends Preferred Stock
DividendsPreferredStock
18938000
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-6389000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14798000
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
800000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
45299000
CY2017 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
59882000
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
700000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45084000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
300000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-10107000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
88000
CY2017 ziop Common Stock Issuance Cost
CommonStockIssuanceCost
2700000
CY2017 ziop Embedded Derivative Dividend Amount
EmbeddedDerivativeDividendAmount
267000
CY2017 ziop Change In Research And Development Expenses
ChangeInResearchAndDevelopmentExpenses
7300000
CY2017 ziop Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
0
CY2017 ziop Effective Income Tax Rate Reconciliation Collaboration Agreement
EffectiveIncomeTaxRateReconciliationCollaborationAgreement
0.00 pure
CY2017 ziop Research And Development Service Agreement Quarterly Payment
ResearchAndDevelopmentServiceAgreementQuarterlyPayment
13000000
CY2017 ziop Operating Loss Carryforwards Research Expiration Dates
OperatingLossCarryforwardsResearchExpirationDates
2037
CY2017 ziop Research And Development Service Agreement Aggregate Payment
ResearchAndDevelopmentServiceAgreementAggregatePayment
39200000
CY2017 ziop Payment For Issuance Of Restricted Common Stock
PaymentForIssuanceOfRestrictedCommonStock
2059000
CY2017 ziop Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development True Up
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp
-0.07 pure
CY2017 ziop Effective Income Tax Rate Reconciliation Nondeductible Expense Officers Compensation
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation
-0.02 pure
CY2017 ziop Effective Income Tax Rate Reconciliation Nondeductible Expense Federal Rate Change
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange
-1.24 pure
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25610894 shares
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.12 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.01 pure
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-58325000
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.57
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8295 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.01 pure
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.43
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.40
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7915 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0127 pure
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y10M17D
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
144100 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.43
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
130391463 shares
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.03 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.00 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0209 pure
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
234833 shares
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.32
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
362800 shares
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
551000
CY2016 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2000
CY2016 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2016 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-124000
CY2016 us-gaap Contracts Revenue
ContractsRevenue
6861000
CY2016 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
87000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-165307000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-165297000
CY2016 us-gaap Interest Paid
InterestPaid
0
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8452000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
0
CY2016 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
714000
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
134000
CY2016 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-172420000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
12452000
CY2016 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-425000
CY2016 us-gaap Depreciation
Depreciation
290000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1852000
CY2016 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-380000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-551000
CY2016 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
7123000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
8452000
CY2016 us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
2000
CY2016 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
0
CY2016 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0
CY2016 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
8452000
CY2016 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
75000
CY2016 us-gaap Dividends Preferred Stock
DividendsPreferredStock
7123000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-6861000
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14377000
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
203000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-788000
CY2016 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
172168000
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
300000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
157791000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1500000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-59664000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
714000
CY2016 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
1500000
CY2016 ziop Common Stock Issuance Cost
CommonStockIssuanceCost
109000
CY2016 ziop Issuance Of Common Stock In Connection With License Agreement
IssuanceOfCommonStockInConnectionWithLicenseAgreement
87000
CY2016 ziop Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
0
CY2016 ziop Effective Income Tax Rate Reconciliation Collaboration Agreement
EffectiveIncomeTaxRateReconciliationCollaborationAgreement
-0.25 pure
CY2016 ziop Issuance Of Preferred Stock In Connection With License Agreement
IssuanceOfPreferredStockInConnectionWithLicenseAgreement
118936000
CY2016 ziop Research And Development Service Agreement Quarterly Payment
ResearchAndDevelopmentServiceAgreementQuarterlyPayment
15000000
CY2016 ziop Payment For Issuance Of Restricted Common Stock
PaymentForIssuanceOfRestrictedCommonStock
1500000
CY2016 ziop Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development True Up
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp
0.00 pure
CY2016 ziop Effective Income Tax Rate Reconciliation Nondeductible Expense Officers Compensation
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation
0.00 pure
CY2016 ziop Effective Income Tax Rate Reconciliation Nondeductible Expense Federal Rate Change
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange
0.00 pure
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2017Q1 us-gaap Contracts Revenue
ContractsRevenue
1597000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-13965000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-19658000
CY2017Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
4171000
CY2017Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
15562000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2016Q1 us-gaap Contracts Revenue
ContractsRevenue
1969000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-12040000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-12019000
CY2016Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
14009000
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.01
CY2016Q2 us-gaap Contracts Revenue
ContractsRevenue
1697000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-131242000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-131200000
CY2016Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
132939000
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2017Q2 us-gaap Contracts Revenue
ContractsRevenue
1597000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13014000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-17727000
CY2017Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
4865000
CY2017Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
14611000
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2016Q3 us-gaap Contracts Revenue
ContractsRevenue
1598000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10914000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-14445000
CY2016Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
3591000
CY2016Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
12512000
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2017Q3 us-gaap Contracts Revenue
ContractsRevenue
1598000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13078000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-17604000
CY2017Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
4903000
CY2017Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
14676000
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2016Q4 us-gaap Contracts Revenue
ContractsRevenue
1597000
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-11111000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-14756000
CY2016Q4 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
3532000
CY2016Q4 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
12708000
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2017Q4 us-gaap Contracts Revenue
ContractsRevenue
1597000
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-13436000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-18272000
CY2017Q4 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
4999000
CY2017Q4 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
15033000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
40000

Files In Submission

Name View Source Status
0001193125-18-067077-index-headers.html Edgar Link pending
0001193125-18-067077-index.html Edgar Link pending
0001193125-18-067077.txt Edgar Link pending
0001193125-18-067077-xbrl.zip Edgar Link pending
d531986d10k.htm Edgar Link pending
d531986dex231.htm Edgar Link pending
d531986dex311.htm Edgar Link pending
d531986dex312.htm Edgar Link pending
d531986dex321.htm Edgar Link pending
d531986dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g531986g48o80.jpg Edgar Link pending
g531986g61d78.jpg Edgar Link pending
g531986g68d31.jpg Edgar Link pending
g531986g89o30.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ziop-20171231.xml Edgar Link completed
ziop-20171231.xsd Edgar Link pending
ziop-20171231_cal.xml Edgar Link unprocessable
ziop-20171231_def.xml Edgar Link unprocessable
ziop-20171231_lab.xml Edgar Link unprocessable
ziop-20171231_pre.xml Edgar Link unprocessable